NCT00161187View on ClinicalTrials.gov

Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

May 31, 2001

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2011

Conditions
Cancer
Interventions
BIOLOGICAL

therapeutic allogeneic lymphocytes

The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.

Trial Locations (1)

08903

Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Medicine and Dentistry of New Jersey

OTHER

NCT00161187 - Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor | Biotech Hunter | Biotech Hunter